Cleerly ISCHEMIA vs Tempus ECG-AF

Cleerly ISCHEMIA offers comprehensive interactive web-based reports and 3D digital models, providing a richer and more detailed user experience for interpreting complex CCTA data. Its integration with PowerScribe further streamlines workflow for radiologists. While Tempus ECG-AF focuses on seamless integration into existing ECG workflows, Cleerly's tools for visual and interactive analysis are more critical for its diagnostic modality.

Cleerly ISCHEMIA provides a comprehensive and personalized assessment of coronary artery disease, including non-invasive fractional flow reserve (FFR) estimation and detailed plaque characterization, which are critical for guiding treatment decisions and are prognostically significant. Tempus ECG-AF offers valuable predictive screening for AF to prevent stroke, but Cleerly's depth of diagnostic insight for CAD, validated against invasive FFR, offers a more profound clinical impact from the tool itself.

Tempus ECG-AF provides clear transparency regarding its CMS reimbursement, including specific CPT codes (0764T and 0765T) and a Medicare rate of $128.90, effective January 1, 2025. While Cleerly ISCHEMIA has achieved a Category I CPT code (75580) for non-invasive FFR estimation, effective January 1, 2024, the explicit and published reimbursement rate for Tempus offers more immediate and predictable financial clarity for healthcare providers.

Tempus ECG-AF demonstrates strong enterprise readiness through its emphasis on deep integration into existing healthcare facility systems, compatibility with major ECG vendors like GE and Philips, and explicit mention of EHR integrations for scalable deployment across hospitals. Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, but Tempus's focus on system-wide workflow integration appears more comprehensive for large-scale adoption.

Cleerly ISCHEMIA's ability to provide non-invasive fractional flow reserve (FFR) estimation and comprehensive coronary plaque characterization from CCTA represents a more profound innovation in understanding the complex pathophysiology of coronary artery disease. While Tempus ECG-AF's predictive capability from a standard ECG is highly innovative and was the first FDA clearance for an AF indication in its category, Cleerly's offering provides a deeper, multi-faceted diagnostic shift in cardiac imaging.

Cleerly ISCHEMIA provides a more explicit and comprehensive array of support resources and documentation, including detailed imaging protocols, billing guidelines, and a payor policy look-up tool on its website. These resources are directly relevant to the practical implementation and financial aspects of using their specific technology, offering clear guidance for providers.